M.L.B. and the players’ association plan to re-evaluate their drug policy in the wake of the autopsy report last week on Tyler Skaggs, the Los Angeles Angels pitcher who had fentanyl, oxycodone and alcohol in his system when he was found dead in a Texas hotel room on July 1.

“There are a lot of factors that come into play in terms of preventing a tragedy from happening, but one tragedy is one too many,” said Dan Halem, M.L.B.’s deputy commissioner. “So we’re going to continue to speak to the union to think of everything possible to try to be in a place where we have no tragedies.”

While M.L.B. does test for opioids — which are classified as drugs of abuse, rather than performance enhancers — in its minor league program, it does not test major leaguers unless it has “reasonable cause.” Tony Clark, the executive director of the players’ association, said that Skaggs’ death had sharpened the union’s focus on the issue, but he stopped short of specifically calling for a change in testing procedures.

“For several reasons, including the tragic loss of a member of our fraternity and other developments happening in the country as a whole, it is appropriate and important to re-examine all of our drug protocols relating to education, treatment and prevention,” Clark said through a spokesman.